Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...

Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...

Shares of vaccine companies fell after a Senate panel voted to advance Robert F. Kennedy Jr.'s nomination to lead the ...

Bourla and Afeyan said they began talking about this new approach in the depths of the pandemic, when they were “partners-slash-competitors,” as Bourla puts it, in the effort to create a vaccine.

The Centers for Disease Control and Prevention abruptly ordered its staff to cease all collaboration with the World Health ...

The bill would implement a moratorium for a decade. “I am not against vaccination in any way,” the freshman lawmaker said.

Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...

"Pfizer just released its list of side effects of its COVID-19 vaccine," multiple Facebook posts said Jan. 26 and 27. The posts included a purported list of 46 Pfizer-BioNtech COVID-19 vaccine side ...

Moderna's mRESVIA joined the market after RSV vaccines from Pfizer and GSK already had established themselves. At the healthcare conference, Moderna lowered expected 2025 revenue to the range of $ ...

Moderna stock gained 14%, shooting up to $48.56 per share Tuesday afternoon. Vaccine-makers Novavax and CureVac similarly rose, soaring 15% and 10%, respectively, while Pfizer gained 2% and GSK ...

Moderna launched RSV vaccine mResvia in 2024 as the third-to-market product behind GSK and Pfizer vaccines. However, the firm's pipeline progress could lead to 2025-27 launches for a covid/flu ...